Julia Foldi, MD, PhD

Articles

Building Treatment Algorithms Around Biomarker-Driven Therapies

July 30th 2025

Panelists discuss how treatment algorithms should differentiate between primary and secondary endocrine resistance, disease burden, and mutation status while looking forward to future combinations with oral selective estrogen receptor degraders (SERDs) and next-generation PIK3CA inhibitors with improved toxicity profiles to enable more effective precision medicine approaches.

Beyond Hyperglycemia: Complete Safety Management for PI3K Inhibitor Combinations

July 30th 2025

Panelists discuss how to manage PIK3CA inhibitor toxicities through frequent early monitoring, patient education about warning signs, use of continuous glucose monitors (CGMs) when needed, and willingness to interrupt treatment and reduce doses while maintaining patients on therapy long term.

Beyond Single Biomarkers: How Emerging Data Might Transform Biomarker Testing

July 23rd 2025

Panelists discuss how the SERENA-6 trial’s approach of serial liquid biopsy monitoring for ESR1 mutations raises important questions about the optimal timing and clinical benefit of molecularly guided therapy switches, with both experts preferring to see overall survival data before changing practice patterns.

Evolving Biomarker Testing Strategies for Earlier Detection in Metastatic Breast Cancer

July 23rd 2025

Panelists discuss how biomarker testing strategies have evolved from second-line to first-line metastatic disease, driven by the availability of targeted agents for PIK3CA and ESR1 mutations, with both tissue and liquid biopsy approaches being used to ensure timely results for treatment decision-making.

Nonclinical Factors and Patient Conversations that Shape Treatment Success

July 16th 2025

Panelists discuss how nonclinical factors including drug costs, insurance coverage, work situations, patient intelligence for complex dosing schedules, and comprehensive pretreatment education about toxicities like hyperglycemia, rash, and diarrhea are crucial for successful implementation of the triplet regimen.

Beyond PIK3CA Status: A Case-Based Approach to Multifactor Inavolisib Selection

July 16th 2025

Panelists discuss how to identify ideal candidates for triplet therapy using a case example, emphasizing the importance of endocrine resistance, disease burden, performance status, and careful management of hyperglycemia risk through baseline hemoglobin A1C (HbA1C) assessment and proactive glucose monitoring strategies.

Precision Medicine: Navigating PI3K Inhibitor Choices in Clinical Practice

July 9th 2025

Panelists discuss how to contextualize inavolisib within the broader landscape of PIK3CA inhibitors, noting its improved tolerability compared with alpelisib while emphasizing the need for individualized treatment selection based on disease burden and the emerging challenge of managing comutations like ESR1.

Time to Chemotherapy Delayed by 2 Years: How Inavolisib Combination Data Might Inform Treatment Sequencing

July 9th 2025

Panelists discuss how the INAVO120 trial’s secondary end point showing delayed time to chemotherapy from 12 to 36 months with the triplet combination provides compelling quality-of-life benefits for patients while acknowledging the challenges of determining optimal treatment sequencing after progression on this regimen.

INAVO120 Final Analysis: Translating Overall Survival Data into Clinical Practice

June 30th 2025

Panelists discuss how the INAVO120 trial's final overall survival analysis showing a 7-month median survival benefit (34 vs 27 months) with inavolisib plus palbociclib plus fulvestrant in PIK3CA-mutated endocrine resistant breast cancer represents promising but complex data, given the low crossover rates and potential need for first-line PIK3CA inhibitor use before patients progress to chemotherapy.

Dr Foldi on T-DXd and Sacituzumab Govitecan in Metastatic Breast Cancer

June 4th 2024

Julia Foldi, MD, PhD, discusses the utility of of T-DXd and sacituzumab govitecan in the treatment of metastatic HER2-low and triple-negative breast cancer.

Dr Foldi on the Evolving Treatment Landscape of ADCs in HER2+ Breast Cancer

June 4th 2024

Julia Foldi, MD, PhD, discusses the evolving role of antibody-drug conjugates in the treatment paradigm for metastatic HER2-positive breast cancer.

Dr Foldi on the Impact of ILD in HER2+ Breast Cancer Treatment

May 29th 2024

Julia Foldi, MD, PhD, discusses interstitial lung disease associated with the use of T-DXd in HER2+ breast cancer.

Dr Foldi on the Evolving Role of T-DXd in HER2+ Breast Cancer

April 17th 2024

Julia Foldi, MD, PhD, discusses the evolving role of treatment with T-DXd in metastatic HER2-positive breast cancer.

x